Holen Sie sich die Stockscreener-App
6.95
6.08%
-0.45
Handel nachbörslich:
6.95
Schlusskurs vom Vortag:
$7.40
Offen:
$7.18
24-Stunden-Volumen:
8,623
Relative Volume:
0.03
Marktkapitalisierung:
$13.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.21M
KGV:
-11.90
EPS:
-0.5842
Netto-Cashflow:
-
1W Leistung:
+9.45%
1M Leistung:
+1,718%
6M Leistung:
+802.60%
1J Leistung:
+488.98%
1-Tages-Spanne:
$6.7325
$7.18
1-Wochen-Bereich:
$6.40
$7.41
52-Wochen-Spanne:
$0.25
$7.50
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Firmenname
Neurosense Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare NRSN vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
6.95 | 13.18M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
NeuroSense to file NDS to Health Canada for PrimeC ALS treatment - scanx.trade
NeuroSense to discuss PrimeC Phase 3 plans in Roth ALS webinar - scanx.trade
NeuroSense H1FY27 Results: Net loss narrows to $3.56M, targets Dec 2026 filing - scanx.trade
NeuroSense Advances PrimeC ALS Program and Cuts Costs in H1 2026 - tipranks.com
Without delays, cash won't fund 12 months under NeuroSense's (NASDAQ: NRSN) original development plan. - Stock Titan
NeuroSense Provides Business Update and Progress for the First Half of 2026 - PR Newswire
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - The Globe and Mail
12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com
NeuroSense (NASDAQ: NRSN) cuts share count to 1.9M in 1-for-20 split - Stock Titan
Why Is NeuroSense (NASDAQ:NRSN) in Focus Before Tuesday’s Open? - Kalkine Media
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
Amyotrophic Lateral Sclerosis Pipeline 2026: FDA Approvals, - openPR.com
NeuroSense Therapeutics (NRSN) Slips 1.24% to $0.41, Hovering Near Key Support at $0.39Parabolic SAR - dars.gov.et
NRSN Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS - Morningstar
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval - TipRanks
NeuroSense redesigns PrimeC ALS plan for faster, cheaper approval path - scanx.trade
NeuroSense Therapeutics Ltd. Warrant (NRSNW) Key Financial Ratios – Valuation, Profitability & More - Value Research
NeuroSense (NRSN) gains 12‑month mandate for reverse share split - Stock Titan
NeuroSense Therapeutics Ltd. Warrant (NRSNW) Peer Comparison – Compare with Others - Value Research
NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN - TradingView
12 Health Care Stocks Moving In Tuesday's After-Market SessionAlector (NASDAQ:ALEC), NeuroSense Therap - Benzinga
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - vinanet.vn
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session: Support at $0.36 and Resistance at $0.40 Frame the Range for the Current SessionThrowback Trade - siam.in
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - The Globe and Mail
Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com
NeuroSense Issues CEO Letter to Shareholders - Nasdaq
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et
Global Neurodegenerative Disease Market is Expected to - GlobeNewswire
NRSN Q2 2025 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Pipeline Advances - dars.gov.et
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - GuruFocus
Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan
NeuroSense Therapeutics (NRSN) Jumps 11.35% to $0.52, Nears Key Resistance at $0.55Chart Pattern Alerts - dars.gov.et
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
NeuroSense Therapeutics Ltd. SEC Filing (Aug 3, 2026) - Stock Titan
NRSN Q2 2025 Earnings: Narrower-than-Expected Loss Highlights Clinical-Stage DisciplineShare Dilution Risk - dars.gov.et
NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split - TipRanks
NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push - Stock Titan
NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective - tipranks.com
NeuroSense Therapeutics (NRSN) sets $150M shelf and $3.8M ATM share plan - Stock Titan
NeuroSense Therapeutics (NRSN) Plunges 14% – Testing Critical Support at $0.46Sentiment Shift - vinanet.vn
Neurosense Therapeutics is a buy, this analyst says - Cantech Letter
Neurosense Therapeutics Ltd expected to post breakeven results a shareEarnings Preview - TradingView
Neurosense Therapeutics Ltd. Revenue Breakdown – FWB:H1Z - TradingView
Neurosense Therapeutics Ltd - TradingKey
Neurosense Therapeutics Ltd (NRSN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSN) Cash Flow - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.602|Chg%:-0.048 - TradingKey
Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):